A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol - Takeaways - MDSpire

A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol

  • By

  • Kyong Hye Joung

  • Bon Jeong Ku

  • July 10, 2026

  • 0 min

Share

  • 1

    The PIVOT study is a multicenter, observational trial assessing LivaloZet® tablets in Korean adults with dyslipidemia and metabolic syndrome.

  • 2

    The primary endpoint is the percent change in low-density lipoprotein cholesterol (LDL-C) from baseline at Week 24.

  • 3

    Secondary endpoints include LDL-C changes at Week 48 and changes in the full lipid panel and LDL-C target achievement rates.

  • 4

    Safety assessments will monitor adverse events, laboratory tests, and vital signs for statin-related hepatotoxicity and myopathy.

  • 5

    The study aims to provide real-world evidence on the effectiveness and safety of a pitavastatin/ezetimibe combination in this patient population.

Original Source(s)

A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol

  • by Kyong Hye Joung, Bon Jeong Ku

  • July 10, 2026

Related Content

2026 Lipid Guidelines Beyond Statins:  Non- Statin Agents to Manage Dyslipidemias

Dr. Talreja  discusses the 2026 standard of care for treatment of dyslipidemia with new screening guidelines and advanced therapy options.

  • June 12, 2026

  • 1 min
ASE Plenary: Progress, Priorities, and What’s Next

Efforts to align, sustain, and engage drove a year of growth for ASE.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.